Cystic Fibrosis Research
Cystic fibrosis (CF) is a common inherited disease that mostly affects the lungs and airways of a sufferer. One of the main pathological characteristics of CF is the failure of airway defence against bacterial infection, leading to frequent chest infection and progressive lung damage.
Cystic Fibrosis Research Products Targets
Products for Cystic Fibrosis Research - Page 11
- Cat.No. Product Name Information/Activity
-
BCC8081
cAMPS-Sp, triethylammonium salt
93602-66-5
-
BCC8078
8-Bromo-cAMP, sodium salt
8-Bromo-cAMP sodium salt (8-Br-Camp sodium salt), a cyclic AMP analog, is an activator of cyclic AMP-dependent protein kinase (PKA).
-
BCC7868
Bisindolylmaleimide II
137592-45-1
-
BCC6687
C-1
HA-100 is an inhibitor of cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase with IC50s of 4, 8, 12 and 240 μM, respectively.
-
BCC7131
Calphostin C
121263-19-2
-
BCC7363
CGP 53353
145915-60-2
-
BCC6778
Dihydrosphingosine
3102-56-5
-
BCC1100
Enzastaurin (LY317615)
Enzastaurin is a potent and selective PKCβ inhibitor with an IC50 of 6 nM, showing 6- to 20-fold selectivity over PKCα, PKCγ and PKCε.
-
BCC3704
GF 109203X
Bisindolylmaleimide I (GF109203X) is a highly selective, cell-permeable, and reversible protein kinase C (PKC) inhibitor with a Ki of 14 nM.
-
BCC3705
Go 6983
Go 6983 is a pan-PKC inhibitor against for PKCα, PKCβ, PKCγ, PKCδ and PKCζ with IC50 of 7 nM, 7 nM, 6 nM, 10 nM and 60 nM, respectively.
